Drug approval in Europe: your complete end-to-end partner for market entry
Entering the European pharmaceutical market requires far more than a well-prepared regulatory dossier. For any company seeking drug approval in Europe — whether it is your first international market or an expansion of an existing global portfolio — success depends on assembling a compliant, fully operational European infrastructure: a legally established presence, qualified personnel, a functioning pharmacovigilance system, GMP-compliant importation and batch release arrangements, and robust post-approval compliance processes.
Building this across multiple service providers is one of the most common sources of costly, avoidable delays.
The challenge is compounded for sponsors of complex or specialized products. Advanced therapy medicinal products (ATMPs), radiopharmaceuticals, biosimilars, biological medicines, and veterinary medicinal products each carry distinct regulatory, manufacturing, and quality requirements. Fragmented advisory support rarely meets the standard needed to navigate these categories through European regulatory procedures with confidence.
Billev Pharma East was built to address this gap. We serve as a single, integrated European regulatory partner for human and veterinary medicinal products — covering regulatory strategy, marketing authorization, GMP importation, batch release, pharmacovigilance, and ongoing lifecycle management. Everything your product needs to reach and remain on the European market, under one roof.
What does successful drug approval in Europe actually require?
Obtaining a marketing authorization is only one milestone in a much longer regulatory journey. Before a medicinal product can be placed on the European market, companies must select the appropriate regulatory pathway, prepare a compliant Common Technical Document (CTD) dossier, establish regulatory and quality oversight, and ensure that all pre- and post-approval obligations can be sustainably fulfilled.
In the European Union, human medicinal products may be authorized through the Centralized Procedure (EMA), Decentralized Procedure, Mutual Recognition Procedure, or national procedures. Veterinary medicinal products are governed by a separate regulatory framework under Regulation (EU) 2019/6, with its own dossier requirements, procedure routes, and post-authorization obligations. The optimal pathway depends on product type, target markets, data package, and commercial strategy — and these decisions must be made before submission activities begin.
For ATMPs, radiopharmaceuticals, biosimilars, biological medicines, and veterinary products, additional complexity arises from product-specific manufacturing requirements, comparability exercises, GMP classification challenges, and dedicated scientific guidance. These categories require specialized expertise at every stage — not only in regulatory affairs, but also in GMP oversight, importation, quality release, and pharmacovigilance.
Post-authorization obligations are equally demanding. Marketing authorization holders must maintain pharmacovigilance systems, manage variations and renewals, keep product information current, oversee batch release arrangements, and demonstrate ongoing compliance throughout the product lifecycle. Companies that do not plan for these requirements before authorization is granted frequently face avoidable delays, inspection findings, and increased costs after launch.